Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T46128
|
||||
Former ID |
TTDI02331
|
||||
Target Name |
Melanocytes lineage-specific antigen GP100
|
||||
Gene Name |
PMEL
|
||||
Synonyms |
ME20M; ME20S; Mbeta; Melanocyte protein PMEL; Melanocyte protein Pmel 17; Melanomaassociated ME20 antigen; P1; P100; Premelanosome protein; Silver locus protein homolog; PMEL
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Melanoma [ICD9: 172; ICD10: C43] | ||||
Function |
Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity.
|
||||
BioChemical Class |
PMEL/NMB family
|
||||
UniProt ID | |||||
Sequence |
MDLVLKRCLLHLAVIGALLAVGATKVPRNQDWLGVSRQLRTKAWNRQLYPEWTEAQRLDC
WRGGQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDGQVIWVNNTIINGSQVWGGQP VYPQETDDACIFPDGGPCPSGSWSQKRSFVYVWKTWGQYWQVLGGPVSGLSIGTGRAMLG THTMEVTVYHRRGSRSYVPLAHSSSAFTITDQVPFSVSVSQLRALDGGNKHFLRNQPLTF ALQLHDPSGYLAEADLSYTWDFGDSSGTLISRALVVTHTYLEPGPVTAQVVLQAAIPLTS CGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEVVGTTPGQAPTAEPSGTTSVQVPTTEVIS TAPVQMPTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGMTPAEVSIVVLSGTTAAQVTT TEWVETTARELPIPEPEGPDASSIMSTESITGSLGPLLDGTATLRLVKRQVPLDCVLYRY GSFSVTLDIVQGIESAEILQAVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRL CQPVLPSPACQLVLHQILKGGSGTYCLNVSLADTNSLAVVSTQLIMPGQEAGLGQVPLIV GILLVLMAVVLASLIYRRRLMKQDFSVPQLPHSSSHWLRLPRIFCSCPIGENSPLLSGQQ V |
||||
Drugs and Mode of Action | |||||
Drug(s) | Melanoma vaccine | Drug Info | Phase 3 | Melanoma | [521514] |
Multi-epitope peptide melanoma vaccine | Drug Info | Phase 3 | Melanoma | [521514] | |
Gp100:209-217(210M) peptide vaccine | Drug Info | Phase 2 | Melanoma | [521456] | |
IMCgp100 | Drug Info | Phase 2 | Melanoma | [889433] | |
Multi-epitope tyrosinase/gp100 vaccine | Drug Info | Phase 2 | Melanoma | [521451] | |
AE-08 | Drug Info | Phase 1 | Melanoma | [549441] | |
Melanoma vaccine | Drug Info | Discontinued in Phase 2 | Melanoma | [547218] | |
Modulator | IMCgp100 | Drug Info | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
References | |||||
Ref 521451 | ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health. | ||||
Ref 521456 | ClinicalTrials.gov (NCT00003895) Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma. U.S. National Institutes of Health. | ||||
Ref 521514 | ClinicalTrials.gov (NCT00036816) Vaccine Therapy in Treating Patients With Melanoma of the Eye. U.S. National Institutes of Health. | ||||
Ref 547218 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014153) | ||||
Ref 521451 | ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health. | ||||
Ref 530817 | Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7. | ||||
Ref 531162 | Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.